Zinc Lozenges and the Common Cold: Form, Dose, and the Timing Window

This episode explains one of the few cold remedies with a plausible, tested effect, and why that effect may not apply to most of what you can buy. The claim is narrow. Zinc may shorten a cold, but the evidence points to a particular kind of lozenge, taken at a particular daily dose, started very early. The research also carries real disagreement, and it carries a risk if the dose is pushed too high. We'll take these in order. Start with where the idea came from. According to the meta-analysis comparing zinc acetate and zinc gluconate, the field began with a small story. A three-year-old girl had cold symptoms, and her symptoms vanished after she dissolved a therapeutic zinc tablet in her mouth instead of swallowing it. That observation suggested something local, an effect in the throat and pharynx rather than something absorbed into the blood and delivered through the body. That distinction is the first key idea. The benefit seems tied to slow dissolution in the mouth. Wikipedia's entry on zinc and the common cold notes that this effect has not been reported for ordinary oral zinc tablets, the kind you swallow. So when people say zinc helps colds, the accurate version is narrower: zinc lozenges, dissolved slowly, appear to help. A zinc capsule swallowed with water is a different intervention, and the lozenge trials say little about it. A recap before moving on. The benefit appears linked to the zinc sitting in the mouth and throat as the lozenge dissolves. That raises the next question: what does a lozenge need to do for that local effect to happen? The answer is chemistry. Zinc has to be released as free ions to do anything in the throat. If the lozenge's other ingredients grab onto the zinc and hold it, the zinc is in the product but not available. The meta-analysis explains that citric acid binds zinc tightly, so little or none is released. It also lists tartaric acid, sodium bicarbonate, mannitol, sorbitol and certain oils as ingredients implicated in trials that failed. A lozenge can print a generous zinc number on the label and still deliver almost no free zinc. This is why the choice of zinc salt gets so much attention. Harri Hemilä, of the University of Helsinki, explains that acetate binds zinc only weakly, which is why the researcher George Eby proposed it as the ideal salt: it lets go of the zinc readily. Gluconate is the other salt with trial data. Here is the first key number, and the debate it sits inside. Across seven lozenge trials with 575 people, colds were shortened by about 33 percent on average. The 95 percent confidence interval ran from 21 to 45 percent. That interval is a range of plausible values for the true effect. So the best single estimate is about a third shorter, but the true figure could reasonably be anywhere from roughly a fifth to nearly half. Put plainly: about a third shorter, give or take a wide margin. Now the comparison between salts. Three trials used acetate and found colds shortened by about 40 percent. Four trials used gluconate and found about 28 percent. That looks like acetate winning. But the gap of twelve points was not statistically significant, which means it could be explained by chance alone. When one outlier gluconate trial was set aside, the two salts converged to 40 percent versus 38 percent. On this reading, the salt barely matters. There is a fair opposing view, and it deserves its full weight. The CMAJ meta-analysis of 17 trials found a significant benefit for acetate, about two and two-thirds days shorter, but not for gluconate or sulfate, and the statistical test for a difference between them was significant. So one analysis says acetate is better and another says the salts are equivalent. The CMAJ authors themselves cautioned that this may be an artefact of who was studied: acetate was used only in adults, and sulfate only in children. If children respond differently, the salt and the age group are tangled together. The CMAJ review found adults shortened by about two and a half days while children showed no significant effect. The authors offer possible reasons, such as different viruses or dosing problems, but none is established. So the honest position is that acetate may be better, may be equal, and the data cannot fully separate the salt from the population. What the sources do support is the point underneath the argument. Whichever salt you prefer, it only works if the lozenge releases free zinc. The recipe may matter as much as the salt. A recap of this stretch. The salt may matter less than whether free zinc is actually released. And that is where most shelf products fall short. Hemilä states that most marketed lozenges contain too little zinc or contain zinc-binding ingredients, so the trial findings are, in his words, not directly applicable to the wide variety of products on shelves. The trials tested specific formulations. A shop lozenge that shares the word zinc with them is not the same intervention. Now dose and timing, the third key idea, which is also contested. The strongest dose evidence comes from three trials of zinc acetate lozenges at 80 to 92 milligrams of zinc per day. Those trials had 102 people in the zinc groups and 97 on placebo. Pooled, colds were about 42 percent shorter, and the 95 percent interval ran from 35 to 48 percent. Wikipedia, reporting the same patients, gives 36 percent, which works out to about 2.7 days, and a threefold recovery rate. These are two framings of the same data. The BMC Primary Care analysis also found nasal discharge reduced by 34 percent and congestion by 37 percent. Then there is the question of whether more helps. In the main meta-analysis, doses of 80 to 92 milligrams a day gave a 33 percent reduction, while doses of 192 to 207 milligrams a day gave 35 percent. That is essentially the same. More was not clearly better, and the authors suggest an optimal composition may peak near 80 milligrams a day. Wikipedia's summary agrees that no evidence showed doses over 100 milligrams a day working better. Dosing pattern matters too. Two trials, one by Mossad and one by Prasad, gave 13 milligrams per lozenge six times a day, and both found colds about 45 percent shorter. Another gluconate trial used 23 milligrams every two hours while awake, after a 46 milligram loading dose. Hemilä notes that dissolving one 80 milligram lozenge is probably not equivalent to dissolving eight 10 milligram lozenges, and the best frequency remains unstudied. I'm reporting what the trials used, not suggesting any regimen. On timing: two of the three high-dose acetate trials began within 24 hours of symptom onset. The BMC Primary Care authors conclude that the strongest evidence of benefit is for such rapid initiation. Note the wording. It is the strongest evidence, not proof that later starts fail. There is even a tension here: Wikipedia notes that longer colds saw greater reductions, which sits awkwardly with an early-start message. So how rigid the 24-hour window really is remains open. Before the risks, a recap of the sweet spot the strongest evidence points to: roughly 80 to 92 milligrams a day, from a lozenge that actually releases zinc, started within 24 hours of symptoms. Now the part where the evidence is contested, because it should not be skipped. Hemilä calls the evidence very strong, noting the included trials were randomised, double-blind and placebo-controlled. The CMAJ review disagrees in tone. It pooled 17 trials with 2,121 people, found about 1.65 days shorter on average, but with very high heterogeneity, meaning the trials disagreed widely with each other. It rated the quality of evidence moderate to low and called efficacy uncertain. The 2024 Cochrane review, as summarised on Wikipedia, also found low-certainty evidence. There is a null result too. A 2020 randomised trial of a commercial acetate lozenge found no benefit. Possible reasons include a short five-day course, a low daily dose, or the formulation itself. It also saw a slowed recovery rate after treatment stopped, though whether that rebound is real is unresolved. A BMJ Open paper notes twelve controlled studies found no benefit. So the claim is not settled. Then the risks of too much. The CMAJ analysis found more adverse events with zinc, a relative risk of 1.24. Bad taste was more common, at 1.65 times, and so was nausea, at 1.64 times. Those are relative figures, meaning how much more often compared with placebo, not how many people were affected. Beyond that, the BMC Primary Care authors describe long-term high-dose zinc reducing copper levels and causing blood changes, which were completely reversed after stopping. Zinc and copper compete for absorption, which is the usual explanation for copper depletion. Doses of 100 to 150 milligrams a day have been given for months with few adverse effects. But how common copper depletion is at 80 to 90 milligrams a day for one or two weeks is unknown, since the sources describe it only for long-term use. Separately, nasal zinc is a different matter: the FDA warned in June 2009 about loss of smell. So, the thesis. Zinc may help, but the evidence concerns slow-dissolving lozenges, probably around 80 to 92 milligrams a day, started within a day of symptoms, and most products do not match that. The strongest result is about 42 percent shorter colds, the broader estimate about a third, and the acetate-versus-gluconate gap may just be chance. The quality of the evidence is debated, one commercial-lozenge trial found nothing, and prolonged high doses can deplete copper. A concrete takeaway: if you ever weigh a zinc lozenge, check what the label actually lists. Look for the elemental zinc amount per lozenge, and for ingredients such as citric acid, sorbitol or mannitol that the failed trials implicated. A product with low zinc or those ingredients does not resemble what was tested. What remains unresolved is considerable: the best lozenge composition and frequency, how rigid the 24-hour window is, why adults and children differ, how common copper depletion is over a short course, and whether the rebound is real. This is general education, not personal medical guidance.